BC Cancer - Vancouver

600 W 10th Avenue
Vancouver, BC V5Z 4E6

Clinical Trial Unit Manager
Darko Curman
604-877-6000 x673226
dcurman@bccancer.bc.ca

Bladder

NILE: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Cancer Type
Bladder
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

BL.13: A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Cancer Type
Bladder
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

TROPiCS-04: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

Cancer Type
Bladder
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

PROOF 302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations 

Cancer Type
Bladder
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

EV-302: An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Cancer Type
Bladder
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov
Back to top